Teva Reports Second Quarter 2022 Financial Results | Business Wire
Industrial Investor Pays $24M for Teva's Irvine Campus - Orange County Business Journal
Investors question green tint of Teva's $5bn sustainability bond | Financial Times
Teva ponies up $420M to settle with investors who said company hid price-fixing scheme | Fierce Pharma
Teva Pharmaceuticals Portfolio Investments, Teva Pharmaceuticals Funds, Teva Pharmaceuticals Exits
Teva Stock Skyrockets After Inking North Of $4 Billion In Opioid Settlements | Investor's Business Daily
Earnings Preview: It's a mixed bag for Teva Pharma in Q3 | AlphaStreet
Teva Pharmaceutical Industries — 9 Portfolio companies, 10 Investments, Team — Unicorn Nest
Teva Pharmaceuticals - Wikipedia
Analysis: Teva Pharmaceuticals is bogged down by legal issues, fails to kick-start growth | Ctech
Teva Reports Earnings Tomorrow. Here's What to Expect. | Barron's
Teva Bonds: 8.8% Yield To Maturity Understates Upside | Nasdaq
6 Reasons I've Been Aggressively Buying Teva Pharmaceutical Industries | The Motley Fool
NuPathe acquired by Teva for $144M - Technical.ly
Teva Pharmaceutical: Investment Opportunity During Fed Rate Hike (NYSE:TEVA) | Seeking Alpha
Teva Pharmaceuticals will pay $420 million in a federal case
Teva Pharmaceutical to Nominate Four New Directors - WSJ
Jewish Values Investors JLens Target Israeli Company
Teva Pharmaceuticals has acquired success with Actavis Generics | World Finance
Teva Pharmaceutical Industries Adds US$389m To Market Cap, But Investors Still Down 47% From Five Years Ago - Simply Wall St News
Five Considerations After Teva Pharmaceuticals' Q3 Report (NYSE:TEVA) | Seeking Alpha
Teva Selling $3.5 Billion of Junk Bonds to Refinance Debt - Bloomberg
Suffering from missteps, drugmaker Teva struggles to heal own ills | The Times of Israel
Why the Teva Pharmaceuticals Stock Rebound May Be Real | InvestorPlace
